Definitive Contract HHSN261201200095C

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI) to Myriad RBM, Inc. for the development of a clinical automated multiplex affinity capture technology to detect low abundance cancer-related proteins and peptides. The contract has a firm fixed price of $1,126,627.00 and was awarded on September 28, 2007, with a scheduled completion date of June 27, 2010. As an SBIR Phase I contract, this award represents the initial research and...

This contract was awarded by the National Cancer Institute to Proteios Technology, Inc., a self-certified small disadvantaged business. The $455,000 firm-fixed-price contract is for a 1-year Small Business Innovation Research (SBIR) Phase I project focused on developing a new paradigm for autologous and allogeneic cell therapy manufacturing. The contract is part of the NCI's SBIR program, which aims to stimulate technological innovation and increase commercialization of federal research and...

This is a $148,828 Small Business Innovation Research (SBIR) Phase I contract awarded by the Department of Health and Human Services (HHS) to Meso Scale Diagnostics LLC, a small business provider of assay development services, laboratory testing equipment, and immunoassays. The contract, titled "TOPIC 238 AUTOMATED MULTI-ARRAY PLATFORM FOR CANCER BIOMARKERS," is for the development of an automated platform to detect cancer biomarkers. As a Phase I SBIR contract, this award is...

<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Pharmaseq, Inc. The contract is for the development of an &quot;Antibody Array for Cancer Detection&quot; under SBIR Topic 236. The contract has a firm fixed price ceiling value of $150,000.00 and a period of performance ending on March 29, 2009. The contract is designated as a Total Small Business Set-Aside.</p>

<p>The U.S. government awarded a $150,000.00 Small Business Innovation Research (SBIR) Phase I contract to Advansta Inc., a self-certified small disadvantaged business, for the development of an antibody array for cancer detection. The contract was awarded by the Department of Health and Human Services (HHS) on September 28, 2007 and has a firm fixed price pricing type. The place of performance is West Menlo Park, CA 94025, USA, and the ultimate completion date is June 27, 2008.</p>

This is a $992,088.91 Phase II Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) Department of Health and Human Services (HHS), to Rockland Immunochemicals Inc., a for-profit small business corporation. The contract is for the development of a &quot;Pharmacodynamic Assay for AKT for Use with PI3K/AKT/mTOR Inhibitors&quot; under SBIR Topic 229. As a Phase II SBIR award, this follows a previous Phase I...

This is a $300,000.00 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institutes of Health (NIH) National Cancer Institute to Base Pair Biotechnologies Inc., a for-profit company that provides custom aptamer development services and products to the federal government. The contract is for the &quot;Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics&quot;, which was one of the research topics identified in the...

This is a $197,673 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a part of the Department of Health and Human Services (HHS), to Molecular Express, Inc., a minority-owned and self-certified small disadvantaged business. The contract is for the development of a commercial point-of-care device capable of electronically sensing tumor cells and molecular cancer biomarkers in a patient's circulating peripheral blood. This research project...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the U.S. Department of Health and Human Services (HHS) to Allele Biotechnology and Pharmaceuticals, Inc. for the development of novel protein expression technologies for glycosylated cancer-related proteins. The contract has a ceiling value of $150,000 and was awarded on September 30, 2009, with a completion date of March 30, 2010. Allele Biotechnology is a minority-owned, for-profit small business based in San...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI) to Siloam Biosciences, Inc., a minority-owned, for-profit manufacturer of goods. The contract, with a ceiling value of $198,570.00, is for the development of a &quot;LOW VOLUME, ULTRA-SENSITIVE IMMUNODIAGNOSTIC SYSTEM&quot; under Topic 309. The contract is a Firm Fixed Price Definitive Contract with a completion date of June 27, 2013. The contract is set aside for small...